Prognostic impact of AJCC response criteria for neoadjuvant chemotherapy in stage II/III breast cancer patients: breast cancer subtype analyses

BACKGROUND: Neoadjuvant chemotherapy (NAC) is a standard treatment for stage II/III breast cancer patients, and response to NAC is a useful prognostic marker. Since its introduction, 6–8 cycles of NAC has become the standard regimen to improve the outcome of these patients. The purpose of this study...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:BMC Cancer
Main Authors: Yang, Yaewon, Im, Seock-Ah, Keam, Bhumsuk, Lee, Kyung‑Hun, Kim, Tae‑Yong, Suh, Koung Jin, Ryu, Han Suk, Moon, Hyeong-Gon, Han, Sae‑Won, Oh, Do‑Youn, Han, Wonshik, Kim, Tae‑You, Park, In Ae, Noh, Dong-Young
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2016
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4955253/
https://ncbi.nlm.nih.gov/pubmed/27444430
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-016-2500-1
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados